The roundup also covers telehealth firms marketing off-label GLP-1s for addiction and a Treasury rule adding scrutiny to licensing deals with Chinese biotechs.
Recap by typeshit. Full story at STAT.
The rise was driven by new generics and steady prices, with Eli Lilly's tirzepatide named in the market breakdown.
The GLP-1 Bridge pilot runs through 2027 and covers approved pills and shots for eligible Part D and Advantage enrollees, with no deductible.
KMOV shares an InvestigateTV+ piece on the national weight loss trend and what coverage your insurance plan might offer. Details are thin in the clip.
Le Figaro reports the tablet arrives in early November. Unlike the Wegovy injection, it won't be covered by France's public reimbursement system.
Endpoints News
Endpoints News looks at big studies moving GLP-1s beyond diabetes and obesity into addiction, a use the public has speculated about for years.
The endocrinologist says fear, judgment and misinformation still shape how people see GLP-1 drugs, and asks patients to learn before deciding.
Loading…